Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 12/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17260656 | 0.78 | MAPT (0.47) | MAPTENPP2HTR1A | |
| SCHEMBL17260692 | 0.77 | CA12 (0.56) | KDM1APDE3BPDE3AMAPT | |
| SCHEMBL19048005 | 0.76 | KDM1A (0.63) | KDM1A | |
| SCHEMBL2026158 | 0.74 | ALDH1A1 (0.50) | KDM1APDE3BPDE3AHPGDMAPT | |
| SCHEMBL3640425 | 0.74 | ALDH1A1 (0.50) | KDM1APDE3BPDE3AHPGDMAPT | |
| SCHEMBL246056 | 0.73 | MAPT (0.43) | KDM1APDE3BPDE3AMAPTENPP2 | |
| SCHEMBL17260641 | 0.73 | ACHE (0.56) | KDM1A | |
| SCHEMBL7402955 | 0.72 | MAOB (0.70) | KDM1AMAPT | |
| SCHEMBL19139451 | 0.72 | NOS1 (0.46) | KDM1APDE3BPDE3AMAPT | |
| SCHEMBL17260646 | 0.71 | NFE2L2 (0.44) | NFE2L2HPGDGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226452-B2 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-12 | — | — | US | disclosed |
| US-10226452-B2 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-06-29 | — | — | US | disclosed |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-06-29 | — | — | US | disclosed |
| WO-2015173168-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226452-B2 | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments | ASAH1, ASAH2, ACER2 | NFE2L2 2226/4885KDM1A 1580/4885PDE3B 1284/4885 |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | ASAH1, ASAH2, ACER2 | NFE2L2 2226/4885KDM1A 1580/4885PDE3B 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.